Patents by Inventor Brian Elliott

Brian Elliott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bispecific antibodies against CD3 and CD20
    Patent number: 12435154
    Abstract: The present invention relates to bispecific antibodies (bsAbs) and the use of such antibodies in the treatment of disease in subjects. Moreover, advantageous treatment regimens are provided for the treatment of B-cell Non-Hodgkin Lymphoma (B-NHL).
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: October 7, 2025
    Assignee: GENMAB A/S
    Inventors: Tahamtan Ahmadi, Manish Gupta, Tommy Li, Roberto Oliveri, Dena Demarco, Ida Hiemstra, Christopher Chiu, Brian Elliott, Ada Azaryan
  • BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20
    Publication number: 20250304689
    Abstract: The present invention relates to bispecific antibodies (bsAbs) and the use of such antibodies in the treatment of disease in subjects. Moreover, advantageous treatment regimens are provided for the treatment of B-cell Non-Hodgkin Lymphoma (B-NHL).
    Type: Application
    Filed: April 13, 2023
    Publication date: October 2, 2025
    Inventors: Brian ELLIOTT, Christopher W.L. CHIU, Nurgul KILAVUZ, Mariana SACCHI
  • Expandable data object management and indexing architecture for intersystem data exchange compatibility
    Patent number: 12248513
    Abstract: A group-based communication platform is configured to ascertain the relatedness of various work objects shared among users of the group-based communication platform. Moreover, the group-based communication platform may further receive and process work objects originating from non-users of the group-based communication platform, thereby further expanding the utility of the determined relatedness between work objects. These work objects (or encrypted representations of these work objects) may be indexed and stored in association with the group-based communication platform, thereby enabling users to search for and retrieve work objects originating from a plurality of work object sources simultaneously, and based on various characteristics of those work objects and the determined interrelatedness between various work objects.
    Type: Grant
    Filed: September 27, 2023
    Date of Patent: March 11, 2025
    Assignee: Salesforce, Inc.
    Inventors: Matthew Wahl, Hubert Florin, Roland Schemers, Brian Elliott, Lydia Han, James McPhail
  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20240301078
    Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
    Type: Application
    Filed: November 2, 2023
    Publication date: September 12, 2024
    Inventors: Brian ELLIOTT, Tahamtan AHMADI, Christopher W.L. CHIU, Esther C.W. BREIJ, Ida HIEMSTRA, Maria N. JURE-KUNKEL
  • BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 FOR TREATING RICHTER'S SYNDROME
    Publication number: 20240174761
    Abstract: Provided are methods of clinical treatment of Richter's syndrome in human subjects using a bispecific antibody which binds to CD3 and CD20.
    Type: Application
    Filed: November 2, 2023
    Publication date: May 30, 2024
    Inventors: Brian ELLIOTT, Rebecca X.M.S. VALENTIN, Daniela HOEHN, Marcia RIOS
  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20240034812
    Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
    Type: Application
    Filed: September 10, 2021
    Publication date: February 1, 2024
    Inventors: Brian ELLIOTT, Tahamtan AHMADI, Christopher W.L. CHIU, Esther C.W. BREIJ, Ida HIEMSTRA, Maria N. JURE-KUNKEL
  • EXPANDABLE DATA OBJECT MANAGEMENT AND INDEXING ARCHITECTURE FOR INTERSYSTEM DATA EXCHANGE COMPATIBILITY
    Publication number: 20240028644
    Abstract: A group-based communication platform is configured to ascertain the relatedness of various work objects shared among users of the group-based communication platform. Moreover, the group-based communication platform may further receive and process work objects originating from non-users of the group-based communication platform, thereby further expanding the utility of the determined relatedness between work objects. These work objects (or encrypted representations of these work objects) may be indexed and stored in association with the group-based communication platform, thereby enabling users to search for and retrieve work objects originating from a plurality of work object sources simultaneously, and based on various characteristics of those work objects and the determined interrelatedness between various work objects.
    Type: Application
    Filed: September 27, 2023
    Publication date: January 25, 2024
    Inventors: Matthew Wahl, Hubert Florin, Roland Schemers, Brian Elliott, Lydia Han, James McPhail
  • Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia
    Patent number: 11858995
    Abstract: Provided are methods of clinical treatment of chronic lymphoblastic leukemia (CLL) in human subjects using a bispecific antibody which binds to CD3 and CD20.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: January 2, 2024
    Assignee: GENMAB A/S
    Inventors: Brian Elliott, Jenny Jianlin Chen, Tahamtan Ahmadi, Christopher W. L. Chiu, Esther C. W. Breij, Ida Hiemstra, Maria N. Jure-Kunkel
  • Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma
    Patent number: 11845805
    Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: December 19, 2023
    Assignee: GENMAB A/S
    Inventors: Brian Elliott, Tahamtan Ahmadi, Christopher W. L. Chiu, Esther C. W Breij, Ida Hiemstra, Maria N. Jure-Kunkel
  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20230355753
    Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL eligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin/carboplatin).
    Type: Application
    Filed: September 10, 2021
    Publication date: November 9, 2023
    Inventors: Brian ELLIOTT, Tahamtan AHMADI
  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING FOLLICULAR LYMPHOMA
    Publication number: 20230357440
    Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and bendamustine.
    Type: Application
    Filed: September 10, 2021
    Publication date: November 9, 2023
    Inventors: Brian ELLIOTT, Tahamtan AHMADI, Christopher W.L. CHIU, Esther C.W. BREIJ
  • Expandable data object management and indexing architecture for intersystem data exchange compatibility
    Patent number: 11809491
    Abstract: A group-based communication platform is configured to ascertain the relatedness of various work objects shared among users of the group-based communication platform. Moreover, the group-based communication platform may further receive and process work objects originating from non-users of the group-based communication platform, thereby further expanding the utility of the determined relatedness between work objects. These work objects (or encrypted representations of these work objects) may be indexed and stored in association with the group-based communication platform, thereby enabling users to search for and retrieve work objects originating from a plurality of work object sources simultaneously, and based on various characteristics of those work objects and the determined interrelatedness between various work objects.
    Type: Grant
    Filed: July 29, 2022
    Date of Patent: November 7, 2023
    Assignee: Salesforce, Inc.
    Inventors: Matthew Wahl, Hubert Florin, Roland Schemers, Brian Elliott, Lydia Han, James McPhail
  • BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA
    Publication number: 20230312757
    Abstract: Provided are methods of clinical treatment of chromic lymphoblastic leukemia (CLL) inhuman subjects using a bispecific-antibody which binds to CD3 and CD20.
    Type: Application
    Filed: September 10, 2021
    Publication date: October 5, 2023
    Inventors: Brian ELLIOTT, Jenny J. CHEN, Tahamtan AHMADI, Christopher W.L. CHIU, Esther C.W. BRElJ, Ida HIEMSTRA, Maria N. JURE-KUNKEL
  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20230312759
    Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL ineligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of car regimen of gemcitabine and oxaliplatin (GemOx).
    Type: Application
    Filed: September 10, 2021
    Publication date: October 5, 2023
    Inventors: Brian ELLIOTT, Tahamtan AHMADI, Patricia GARRIDO CASTRO
  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING FOLLICULAR LYMPHOMA
    Publication number: 20230312758
    Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.
    Type: Application
    Filed: September 10, 2021
    Publication date: October 5, 2023
    Inventors: Brian ELLIOTT, Tahamtan AHMADI, cHRISTOPHER W.L. CHIU, Esther C.W. BREIJ, Ida HIEMSTRA, Maria N. JURE-KUNKEL
  • BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20
    Publication number: 20230227570
    Abstract: The present invention relates to bispecific antibodies (bsAbs) and the use of such antibodies in the treatment of disease in subjects. Moreover, advantageous treatment regimens are provided for the treatment of B-cell Non-Hodgkin Lymphoma (B-NHL).
    Type: Application
    Filed: May 7, 2021
    Publication date: July 20, 2023
    Inventors: Tahamtan AHMADI, Manish GUPTA, Tommy R. LI, Roberto OLIVERI, Dena DEMARCO, Ida HIEMSTRA, Christopher CHIU, Brian ELLIOTT, Ada AZARYAN
  • Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
    Patent number: 11608383
    Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: March 21, 2023
    Assignee: GENMAB A/S
    Inventors: Brian Elliott, Tahamtan Ahmadi, Christopher W. L. Chiu, Esther C. W. Breij, Ida Hiemstra, Maria N. Jure-Kunkel
  • Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma
    Patent number: 11548952
    Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL eligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin/carboplatin).
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: January 10, 2023
    Assignee: GENMAB A/S
    Inventors: Brian Elliott, Tahamtan Ahmadi
  • Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
    Patent number: 11535679
    Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and bendamustine.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: December 27, 2022
    Assignee: GENMAB A/S
    Inventors: Brian Elliott, Tahamtan Ahmadi, Christopher W. L. Chiu, Esther C. W. Breij
  • EXPANDABLE DATA OBJECT MANAGEMENT AND INDEXING ARCHITECTURE FOR INTERSYSTEM DATA EXCHANGE COMPATIBILITY
    Publication number: 20220365968
    Abstract: A group-based communication platform is configured to ascertain the relatedness of various work objects shared among users of the group-based communication platform. Moreover, the group-based communication platform may further receive and process work objects originating from non-users of the group-based communication platform, thereby further expanding the utility of the determined relatedness between work objects. These work objects (or encrypted representations of these work objects) may be indexed and stored in association with the group-based communication platform, thereby enabling users to search for and retrieve work objects originating from a plurality of work object sources simultaneously, and based on various characteristics of those work objects and the determined interrelatedness between various work objects.
    Type: Application
    Filed: July 29, 2022
    Publication date: November 17, 2022
    Inventors: Matthew Wahl, Hubert Florin, Roland Schemers, Brian Elliott, Lydia Han, James McPhail